Recordati Shareholders Revolt Over €10.7bn CVC Take-Private Bid

Key Facts

1Private equity group CVC is facing a revolt from Recordati shareholders over a €10.7 billion take-private offer.

2Investors accuse CVC of pressuring them into selling their stakes at a 'lowball' price.

Amid a shifting landscape for European healthcare M&A, private equity firm CVC Capital Partners is facing a significant revolt from shareholders of the Italian pharmaceutical group Recordati. The conflict centers on a €10.7 billion take-private proposal that has triggered formal opposition from minority investors. According to reports, shareholders accuse CVC of utilizing aggressive tactics to pressure them into exiting their positions at what they deem an unfair valuation.

The core of the dispute lies in the investors' claim that the €10.7 billion offer is a "lowball" price intended to force a delisting without providing adequate premium. This friction highlights growing shareholder activism within large-cap European deals involving private equity buyers. Per analyst facts, the resistance from the investor base could potentially stall the transaction or force a revision of the current terms to satisfy minority stakeholders.

Looking ahead, market participants will be watching for any signals that CVC might raise its bid or adjust its strategy to quell the investor rebellion. As of the close on September 13, 2026, specific price data for the instrument remains unavailable, shifting the focus toward qualitative updates regarding the deal's progress. With no immediate corporate catalysts on the upcoming calendar, the primary driver for the stock will remain the evolving narrative of this takeover battle.